順天醫藥生技股份有限公司

Cellular communication is the process of signal construction to signal transduction. Cell-cell communication (CCC) plays a crucial role in everything from immunity to tissue repair, making it a rich landscape for therapeutic possibilities. The article, "Cell–cell communication: new insights and clinical implications" by Su et al. explores the field of CCC, and its potential for groundbreaking therapeutic interventions. Article link: https://lnkd.in/gGCibfNJ #DrugDiscovery #CellCommunication #Biotech

A recent study titled "Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)" explores the approval landscape for the top 20 pharma companies from 2014 to 2023. According to the authors, the FDA approved 176 new drugs for the 20 leading pharmaceutical companies during the period, while an additional 33 new drugs were acquired through post-approval acquisition. The Big Pharmas launched 83 first-in-class drugs and their share of the industry’s R&D output declined from 72% (2014) to 40% (2023). The authors also found that companies with strong strategic alliances are seeing significantly higher approval rates, streamlining development processes through partnerships allows for faster time to market. With the fierce competition in drug development, partnerships are a necessity to find the right fit to minimize risk, accelerate commercialization, and bring life-saving treatment patients faster. Article link: https://lnkd.in/gaf4-_2G #pharmaceuticals #drugdevelopment #BD #NewDrug

Fierce Biotech's article "Top 10 Smartest Deals in Biopharma" focuses on analyzing some of the most significante and interesting acquisitions in the biopharmaceutical industry and their potential impact and future implications. The Big Pharma companies have been agressively acquiring other companies in recent rears, especially in the areas of ADC, radiopharmaceuticals, and obesity drugs. Article link: https://lnkd.in/gWkBiuz6 #Biotech #Pharmaceutical #DrugDevelopment

Employees at Lumosa Therapeutics rolled up their sleeves and showed their commitment to the community by participating in a blood drive at the Nangang Software Industrial Park. While many of us dedicate our lives to developing life-saving medications, giving blood is a direct and immediate way to make a difference. A special thanks to the Taipei Blood Center Foundation for making this vital service accessible to our employees and the entire park community. #BloodDonation

Convertible notes are financial tools that raise capital and connect to future funding rounds and cash-out events. Jaylon Reynolds' article looks at how convertible notes can be used in fundraising in the pharma industry. These notes provide companies options helping private firms obtain capital while waiting milestones or subsequent funding rounds. Established public companies use these financial tools strategically. New drug development can take a long time and be unpredictable. Convertible notes provide crucial agility, allowing drug development companies to access capital when needed. Valuation methodologies such as scenario analyses, discounted cash flow models, and Monte Carlo simulations help the companies to consider clinical trial outcomes, regulatory milestones, and market penetration potential. Article link: https://lnkd.in/gj9MuVnQ #Fundraising #DrugDevelopment #Pharmaceutical #Biotech

Justin Wilson explores strategic approaches to maximizing ROI in cell and gene therapy innovation in the article titled "Patent Lifecycle Management is Key for Cell and Gene Therapy Innovators," as success in the development of cell and gene therapies (CGTs) requires more than just scientific breakthroughs. For example, companies may face clinical trial challenges, costly and time-consuming development process. However, the rare disease market presents a massive opportunity, with 400 million patients worldwide, and recent approvals like Roctavian for hemophilia A showcase the potential of CGTs. Article link: https://lnkd.in/eedW2pdA #CellandGeneTherapy #Biotechnology #DrugDevelopment

Over the past 50 years, bsAbs have evolved from a promising concept to a clinical reality. Li et al. share the challenges in bsAbs development: tumor mutational burden, t cell activation hurdles, systemic side effects, and off-target toxicities, despite the advantages such as dual-targeting capability, ootential to overcome tumor heterogeneity, and ability to modulate the tumor microenvironment. The authors also look forward to exciting developments on the horizon such as: multispecific bsAbs, neoantigen-targeting bsAbs, NK cell-engaging bsAbs, and in situ bsAb production. Article link: https://lnkd.in/gS9Q2RC4 #Antibody #Cancertreatment #DrugDevelopment

The article "Development of Pharmacological Immunoregulatory Anti-cancer Therapeutics" explores the next generation agents. Article link: https://lnkd.in/gp7bEtHZ

Cancer therapy is undergoing a transformative shift and is reshaping the landscape and creating exciting opportunities for pharmaceutical companies. The article “Monoclonal antibody drugs for cancer: How they work”by Paul et al. summarizes the different approaches used by therapeutic antibodies to target cancer cells, and discusses their mechanisms of action, the structural basis for target specificity, clinical applications and the ongoing research to improve efficacy and reduce toxicity. Article link: https://lnkd.in/gQYM5G45 hashtag#DrugDevelopment hashtag#Antibody

Lumosa is pleased to share the results of clinical trials for Esthesia, which is the brand name of Lumosa’s LT1001 long-acting analgesic injection in Ukraine. The study looked at LT1001 as part of a multimodal approach to manage pain after surgery for patients with injuries from mines and explosives. The study involved 15 patients who received a single 150 mg/2 ml injection of LT1001 intramuscularly 12-24 hours before reconstructive surgery. The study found that pain levels measured by Visual Analogue Scale (VAS) decreased 6 hours after surgery compared to 6-8 hours after giving the drug. Pain relief remained steady for four days after surgery, and researchers found no strong link between Injury Severity Score (ISS) and VAS. The study showed that LT1001 is well tolerated and is effective in postoperative pain management for those having reconstructive procedures due to injuries from mines and explosives.   These findings show how LT1001 could help tackle the tricky issues of easing pain in severe trauma cases. Since injuries from mines and explosives often need complex surgery, and well managed pain control is key for patients to heal and rehabilitate. We believe that LT1001 could play a significant role in improving postoperative care for trauma patients.   As we share these results, we are acutely aware of the ongoing conflict in Ukraine where the study took place. Our hearts go out to all those affected by the war, While our mission is to advance medical science, we hope for a world where treatments for war injuries are no longer necessary.   Link to article: https://lnkd.in/g3sRX3An